‘Unexpected infiltration of meninges by generalised diffuse large b-cell lymphoma manifesting as multiple cranial neuropathies in a patient with history of breast carcinoma’ — authors’ reply

Abstract Primary breast lymphoma (PBL) is an unusual clinical entity accounting for 0.4–0.5% of all breast neoplasms. The usual presentation includes a painless palpable mass similar to that of breast carcinoma. Diffuse large B-cell lymphoma (DLBCL) is the most common identifiable type of PBL based on the histopathological examination. We report an unusual case of 22 years old Bangladeshi woman presented with a 6-month history of a lump on left breast. Although the lump was initially small, it began a rapid growth after 4 months. The swelling was localized and did not show any skin involvement or discharge and as she didn’t have any positive familial history of breast carcinoma her primary attending physician diagnosed it as a case of breast abscess. When local incision and drainage proved ineffective, she was referred to us. After doing an immunohistochemistry from incisional biopsy the diagnosis was confirmed as Diffuse Large B-cell Lymphoma. The patient was treated initially by chemotherapy with CHOP therapy followed by wide local excision. Early and accurate diagnosis of PBL is crucial for selecting the appropriate MDT treatment strategies to avert potentially harmful surgical interventions.

Download Full-text

Primary diffuse large B cell lymphoma (DLBCL) of the prostate presenting with lower urinary tract symptoms (LUTS)

BMJ Case Reports ◽

10.1136/bcr-2020-236280 ◽

2020 ◽

Vol 13 (12) ◽

pp. e236280

Author(s):

Ayesha Nusrat ◽

Syed Muhammad Nazim

Keyword(s):

Urinary Tract ◽

B Cell ◽

Lower Urinary Tract ◽

Cell Lymphoma ◽

B Cell Lymphoma ◽

Large B Cell Lymphoma ◽

Urinary Tract Symptoms ◽

History Of ◽

Large B Cell ◽

Lower Urinary

Malignant lymphomas of the prostate are very rare tumours and are generally not considered in the clinical or pathological diagnosis of prostatic enlargement. We report a case of a 56-year-old man who presented with long-standing history of low back pain and a 2-month history of voiding lower urinary tract symptoms. He denied any history of urinary retention, trauma, catheterisation or any constitutional symptoms. Examination revealed no lymphadenopathy and hepatosplenomegaly. Digital rectal examination showed an irregular, moderately enlarged nodular prostate. His prostate-specific antigen was 1.54 ng/mL. MRI of the pelvis did not show any focal lesion apart from abnormal signal intensity in the central zone. Bone scan was negative. Transrectal ultrasound-guided prostate biopsy revealed diffuse large B cell lymphoma. Bone marrow biopsy and whole body positron emission tomography/CT were unremarkable. The patient achieved complete remission after receiving six cycles of R-CHOP chemotherapy.

Download Full-text

Epstein-Barr virus (EBV)-positive diffuse large B-cell lymphoma arising in patient with a history of EBV-positive mucocutaneous ulcer and EBV-positive nodal polymorphous B-lymphoproliferative disorder

Pathology International ◽

10.1111/pin.12738 ◽

2018 ◽

Vol 69 (1) ◽

pp. 37-41 ◽

Cited By ~ 6

Author(s):

Teerada Daroontum ◽

Kei Kohno ◽

Yoko Inaguma ◽

Akinao Okamoto ◽

Masataka Okamoto ◽

...

Keyword(s):

B Cell ◽

Lymphoproliferative Disorder ◽

Epstein Barr Virus ◽

Cell Lymphoma ◽

B Cell Lymphoma ◽

Barr Virus ◽

Large B Cell Lymphoma ◽

History Of ◽

Epstein Barr ◽

Large B Cell

Download Full-text

Hemophagocytic lymphohistiocytosis secondary to localized large B-cell lymphoma in a patient with history of knee arthroplasty

Leukemia & Lymphoma ◽

10.3109/10428194.2014.958822 ◽

2014 ◽

Vol 56 (5) ◽

pp. 1521-1523 ◽

Cited By ~ 1

Author(s):

Vahid Entezari ◽

Eberechi Agwa ◽

Sory J. Ruiz ◽

Steven A. Lietman ◽

Bernard J. Silver ◽

...

Keyword(s):

B Cell ◽

Knee Arthroplasty ◽

Hemophagocytic Lymphohistiocytosis ◽

Cell Lymphoma ◽

B Cell Lymphoma ◽

Large B Cell Lymphoma ◽

History Of ◽

Large B Cell

Download Full-text

Post-mortem diagnosis of intravascular large B-cell lymphoma

Journal of International Medical Research ◽

10.1177/0300060520924262 ◽

2020 ◽

Vol 48 (6) ◽

pp. 030006052092426

Author(s):

Aniello Maiese ◽

Raffaele La Russa ◽

Alessandra De Matteis ◽

Paola Frati ◽

Vittorio Fineschi

Keyword(s):

B Cell ◽

Cell Lymphoma ◽

B Cell Lymphoma ◽

Lymphoid Cells ◽

Resonance Imaging ◽

Large B Cell Lymphoma ◽

Positron Emission ◽

Atypical Cells ◽

History Of ◽

Large B Cell

Intravascular large B-cell lymphoma (IVLBCL) is a rare (<1%), typically aggressive extranodal variant of mature non-Hodgkin B-cell lymphoma. IVLBCL is characterized by malignant lymphoid cells lodged within blood vessels, particularly capillary channels. Herein, we present a case of a 50-year-old man with a history of myeloradiculitis (∼1 year) and paraparesis requiring hospitalization. During the course of his hospital stay, computed tomography (CT), magnetic resonance imaging, CT-positron emission tomography, and biopsy failed to establish a diagnosis. The patient died 2 months later from bilateral pneumonia. Postmortem examination was undertaken to determine the cause of death. Histologic sections of the patient’s brain, heart, lung, and liver showed aggregates of highly atypical cells bearing enlarged, pleomorphic, and hyperchromatic nuclei. Strong intravascular positivity for CD45 and CD20 markers indicated the cells were of B-cell origin, supporting a diagnosis of IVLBCL.

Download Full-text

Familial risk for non-Hodgkin lymphoma and other lymphoproliferative malignancies by histopathologic subtype: the Swedish Family-Cancer Database

Blood ◽

10.1182/blood-2005-01-0140 ◽

2005 ◽

Vol 106 (2) ◽

pp. 668-672 ◽

Cited By ~ 63

Author(s):

Andrea Altieri ◽

Justo Lorenzo Bermejo ◽

Kari Hemminki

Keyword(s):

B Cell ◽

Hodgkin Lymphoma ◽

Cell Lymphoma ◽

Familial Risk ◽

B Cell Lymphoma ◽

Non Hodgkin Lymphoma ◽

Large B Cell Lymphoma ◽

Swedish Family ◽

History Of ◽

Large B Cell

Abstract Non-Hodgkin lymphoma (NHL) consists of a heterogeneous group of tumors. Population-based data on the familial risk for specific histopathologic subtypes have not been established. Such data are useful for clinical counseling and for searching tumor subtypes sharing common genetic pathways. We used the Swedish Family-Cancer Database to calculate standardized incidence ratios (SIRs) for histopathology-specific subtypes of NHL in 4455 offspring with NHL whose parents or siblings were affected with different types of lymphoproliferative malignancies. A familial history of NHL significantly increased the risk for NHL (SIRparent = 1.8; SIRsibling = 1.9) and for diffuse large B-cell lymphoma (SIRparent = 2.3), follicular lymphoma (SIRsibling = 2.3), and B-cell lymphoma not otherwise specified (NOS) (SIRsibling = 3.4). For a parental history of histopathology-specific concordant cancer, the risks were significantly increased for diffuse large B-cell lymphoma (SIR = 11.8), follicular NHL (SIR = 6.1), plasma cell myeloma (SIR = 2.5), and chronic lymphocytic leukemia (SIR = 5.9). Familial clusters for NHL seemed stronger in females and in siblings. Our study provides the first quantification of the familial risks for NHL by histopathology. The present findings give evidence for a strong familial association of NHL, with little differences in the magnitude of risks for various histopathologic subtypes. The patterns of risks in parents and siblings support the hypothesis of an autosomal-dominant component for diffuse large B-cell NHL and a recessive one for follicular NHL. (Blood. 2005;106:668-672)

Download Full-text

Lenalidomide in Diffuse Large B-Cell Lymphoma

Advances in Hematology ◽

10.1155/2012/861060 ◽

2012 ◽

Vol 2012 ◽

pp. 1-8 ◽

Cited By ~ 13

Author(s):

Catherine Thieblemont ◽

Marie-Hélène Delfau-Larue ◽

Bertrand Coiffier

Keyword(s):

B Cell ◽

Cell Lymphoma ◽

Treatment Options ◽

B Cell Lymphoma ◽

Current Treatment ◽

New Agents ◽

Large B Cell Lymphoma ◽

History Of ◽

Immunomodulatory Drug ◽

Large B Cell

Diffuse large B-cell lymphoma (DLBCL) is the most common form of non-Hodgkin's lymphoma (NHL) in adults. Even if the natural history of DLBCL has been improved with the advent of immunochemotherapy, the survival results obtained with current treatment options clearly indicate that new agents or novel approaches are needed. Lenalidomide (Revlimid, Celgene Corporation, Summit, NJ, USA), an analogue of thalidomide, is an immunomodulatory drug with pleiotropic mechanisms of action potentially adding to immunochemotherapy. We present here the biological rational for the use of lenalidomide in DLBCL in light of recent advances in the pathophysiology of the disease and the therapeutic results of the most recent trials published in literature or reported in meetings in relapsed/refractory situations as well as in first-line treatment.

Download Full-text